Erschienen in:
08.01.2019 | Concise Research Reports
Medicare Formulary Coverage and Restrictions for Opioid Potentiators from 2013 to 2017
verfasst von:
Aishwarya Vijay, BS, Joseph S. Ross, MD, MHS, Nilay D. Shah, PhD, Molly M. Jeffery, PhD, Sanket S. Dhruva, MD, MHS
Erschienen in:
Journal of General Internal Medicine
|
Ausgabe 4/2019
Einloggen, um Zugang zu erhalten
Excerpt
In 2015, 38% of adults used prescription opioids, with slightly higher rates among older adults.
1 Risks of opioids have been well-described and are greater among older adults and when used concurrently with three commonly prescribed “opioid potentiator” drug classes: benzodiazepines, non-benzodiazepine sedative hypnotics, and gabapentinoids.
2, 3 These drugs also have risks when used on their own; in particular, there has been an increasing risk of death associated with benzodiazepine use.
4 …